Mark Martin, Managing Director in the firm’s global Business Services Group, spoke with MM+M about the the potential recapitalizations of PE-backed strategics within the pharma commercialization sector, noting how this is driven by PE firms continuing to place a high value on the favorable underlying tailwinds in this niche of the pharma services segment. He also discussed the changing landscape of agency dynamics, the role of platform integration, and the importance of differentiation across the industry leaders.
Read the full article on MM+M’s site.